Trial Profile
Clinical trial of MGD 006 for the treatment of haematologic cancers
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2013
Price :
$35
*
At a glance
- Drugs Flotetuzumab (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors MacroGenics
- 29 Nov 2013 New trial record